Company Overview of BioMarck Pharmaceuticals, Ltd.
BioMarck Pharmaceuticals, Ltd., a biopharmaceutical company, engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. The company’s lead product is BIO-11006, a novel treatment for chronic obstructive pulmonary disease (COPD). Its BIO-11006 inhibits the function of the myristoylated alanine rich C kinase substrate (MARCKS) protein, which is the vital component for secretion of mucus and inflammatory mediators. The company was founded in 2002 and is based in Durham, North Carolina.
Westpark Corporate Center
4364 South Alston Avenue
Durham, NC 27713-2280
Founded in 2002
Key Executives for BioMarck Pharmaceuticals, Ltd.
Similar Private Companies By Industry
|Accelerated Genetics, Inc.||United States|
|Kemp Biotechnologies Inc.||United States|
|AIKO Biotechnology, Inc.||United States|
|Innovative BioTherapies, Inc.||United States|
|Theragene Pharmaceuticals, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact BioMarck Pharmaceuticals, Ltd., please visit www.biomarck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.